Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in diabetic kidney disease with type 2 diabetes
2015-000990-11Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Finerenone + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Kidney composite endpoint. Started Jun 2015; status: completed.
02
Drugs
finerenone
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-000990-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000990-11.